Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325500 · ClinicalTrials.gov registry record · Phase 2
Incretin Microdosing for Cardiometabolic Health in People With HIV
A Phase 2 study of Weight Gain, sponsored by The University of Texas Health Science Center, Houston.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07325500 is a Phase 2 study of Weight Gain that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants, below the 221-participant average among 38 other Weight Gain trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07325500, a Phase 2 study of Weight Gain, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * To evaluate the tolerability of semaglutide microdosing in adults with HIV. * To evaluate changes in weight, waist circumference (WC) and body mass index (BMI) over 12 weeks (W) of semaglutide weight loss induction and 48 W of semaglutide microdosing therapy.
Conditions Studied
Interventions
- DRUG Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly
- DRUG Dose escalation to 2 mg semaglutide weekly then no semaglutide
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07325500
The ClinicalTrials.gov registry entry for NCT07325500 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 38 other Weight Gain trials with a reported enrollment target (86% lower). The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Weight Gain appearing as the primary indexed condition, and to 2 interventions - of which Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly is the first listed.
NCT07325500 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07325500 about?
NCT07325500 is a clinical study titled "Incretin Microdosing for Cardiometabolic Health in People With HIV". The objectives of this study are as follows: Primary Objective * To determine the rate of weight regain in people living with human immunodeficiency virus (HIV) (PWH) receiving semaglutide microdosing vs. no additional drug following induction therapy. Secondary Objectives * To evaluate the tole...
What is the current status of trial NCT07325500?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-12. Estimated completion is 2029-06-30.
What conditions does trial NCT07325500 study?
This clinical trial studies the following conditions: Weight Gain.
What interventions are being tested in trial NCT07325500?
The interventions under investigation include: Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly (DRUG), Dose escalation to 2 mg semaglutide weekly then no semaglutide (DRUG).
Who is sponsoring clinical trial NCT07325500?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325500 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Gain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
RECRUITING · Phase 2
-
Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers
RECRUITING · Phase 2
-
Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth
COMPLETED · Phase 2
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
RECRUITING · NA
-
Testing Responses of Young Adults to Intervention Messages for Promoting Physical Activity Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.